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Background: People who have a transient ischaemic attack (TIA) or minor stroke are at high risk of a recurrent
stroke, particularly in the first week after the event. Early initiation of secondary prevention drugs is associated with
an 80% reduction in risk of stroke recurrence. This raises the question as to whether these drugs should be given
before being seen by a specialist – that is, in primary care or in the emergency department. The aims of the
RAPID-TIA pilot trial are to determine the feasibility of a randomised controlled trial, to analyse cost effectiveness
and to ask: Should general practitioners and emergency doctors (primary care physicians) initiate secondary
preventative measures in addition to aspirin in people they see with suspected TIA or minor stroke at the time of
referral to a specialist?
Methods/Design: This is a pilot randomised controlled trial with a sub-study of accuracy of primary care physician
diagnosis of TIA. In the pilot trial, we aim to recruit 100 patients from 30 general practices (including out-of-hours
general practice centres) and 1 emergency department whom the primary care physician diagnoses with TIA or
minor stroke and randomly assign them to usual care (that is, initiation of aspirin and referral to a TIA clinic) or
usual care plus additional early initiation of secondary prevention drugs (a blood-pressure lowering protocol,
simvastatin 40 mg and dipyridamole 200 mg m/r bd). The primary outcome of the main study will be the number
of strokes at 90 days. The diagnostic accuracy sub-study will include these 100 patients and an additional 70
patients in whom the primary care physician thinks the diagnosis of TIA is possible, rather than probable. For the
pilot trial, we will report recruitment rate, follow-up rate, a preliminary estimate of the primary event rate and
occurrence of any adverse events. For the diagnostic study, we will calculate sensitivity and specificity of primary
care physician diagnosis using the final TIA clinic diagnosis as the reference standard.
Discussion: This pilot study will be used to estimate key parameters that are needed to design the main study and
to estimate the accuracy of primary care diagnosis of TIA. The planned follow-on trial will have important
implications for the initial management of people with suspected TIA.
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The high risk of stroke following a transient ischaemic
attack (TIA) or minor stroke is now well recognised,
with an untreated risk of recurrence by 90 days around
18% [1,2]. Much of this excess risk is in the first few days
following the initial event [3]. Simple clinical features
(an ABCD2 score, based on age, blood pressure (BP),
clinical features, diabetes and duration) can identify
those people who are at particularly high risk in the first
7 days [4,5]. On this basis, NICE recommends that
people at the highest risk of stroke are seen by a special-
ist within 24 hours of symptom onset (to maximise the
chance that risk-modifying treatment is initiated before
a further event) and people at lower risk of stroke are
seen within 7 days. The National Institute for Health
and Care Excellence (NICE) recommends that 300 mg
aspirin daily is prescribed while awaiting specialist treat-
ment, but no other secondary prevention treatment is
recommended prior to confirmation of diagnosis [6].
Approximately 10,000 recurrent strokes occur within
the first 90 days after TIA and minor stroke each year
[7]. If rapid primary care initiation of secondary preven-
tion drug treatment could reduce 90-day recurrence
rates further from 10% to 2%, this would be equivalent
to preventing 8,000 strokes per year. A reduction in the
national stroke incidence in this 5% to 10% range would
also lead to savings in care costs of the order of £90Mto
£180Mper year in England alone, based upon 2005
National Audit Office calculations.
Evidence that very early treatment reduces recurrent
stroke
There is an emerging evidence base as to what treat-
ments will reduce the risk of stroke in the immediate
days and weeks following TIA. Aspirin is effective when
given as soon as possible [8], and for people with signifi-
cant carotid artery stenosis, carotid endarterectomy is
highly effective as a secondary care surgical procedure:
the number of patients that must be treated to prevent
one ipsilateral stroke within 5 years’ follow-up is five
within a fortnight of the initial stroke or TIA (compared
to 125 after 12 weeks) [9].
There is evidence that cholesterol lowering and blood-
pressure lowering are effective in the long term with
regards to secondary stroke prevention [10,11], but there
is uncertainty with regard to their value in the early
phase. With regard to cholesterol lowering, there was no
evidence of benefit of early administration of simvastatin
in the pilot FASTER trial, which comprised patients with
a TIA or minor stroke within 24 hours of onset who had
been admitted to hospital [12]. Trials of blood-pressure
lowering in the acute phase of stroke are ongoing,
but their findings may be difficult to apply to people
whose symptoms have resolved at the time of treatmentinitiation (that is, people who have had a TIA or minor
stroke).
There is some evidence for dual anti-platelet therapy,
with the pilot FASTER trial finding a lower risk of stroke
in patients receiving clopidogrel plus aspirin compared
to aspirin alone [12], though there was no evidence from
the MATCH trial that in the longer term this combin-
ation was beneficial, with a significantly higher risk of
life-threatening bleeds in the group on combination
therapy [13]. There is, however, some evidence of
longer-term dual anti-platelet therapy benefit from the
ESPRIT and ESPS-2 trials, which found the combination
of aspirin and dipyridamole was superior to aspirin alone
for the treatment of people randomised within 6months
of a TIA or minor stroke [14,15]. The EARLY study
found a lower risk of stroke and a lower risk of a com-
posite of stroke, TIA, myocardial infarction, major bleed-
ing and death (hazard ratio 0.73, confidence interval
0.44 to 1.19) in patients started on aspirin and dipyrid-
amole within 24 hours of initial symptoms versus
patients started on aspirin within 24 hours with dipyrid-
amole started after 7 days, although the results were not
statistically significant [16].
Set against this randomised controlled trial (RCT) evi-
dence of mixed benefit for early initiation of secondary
prevention medications, there has been encouraging ob-
servational data of the beneficial effect of early use of
these drugs from the EXPRESS and SOS-TIA studies
[3,17]. In the EXPRESS study, changing the protocol ata
specialist TIA clinic whereby secondary prevention
drugs (dual anti-platelet therapy, blood-pressure lower-
ing therapy and simvastatin) were commenced on the
same day rather than waiting for the general practitioner
(GP) to commence treatment on receipt of a clinic letter
was associated with an 80% reduction in the risk of
stroke at 90 days. The median delay from prescription of
first treatment fell from 20 days to 1 day. In the SOS-
TIA study, patients with suspected TIA (53% within 24
hours of symptom onset) were seen in a specialist clinic
where a stroke prevention programme was initiated. The
90-day risk of stroke in patients treated in this way was
about 80% lower than would have been anticipated given
their clinical features by applying the ABCD2 score [5].
Why is a trial of early treatment in primary care
necessary?
Many patients with TIA suffer a stroke before they are
seen by a specialist, and it is likely that some of these
strokes are preventable by earlier initiation of secondary
prevention by the first doctor to see the patient, either
in primary care or an emergency department.
In the NORTHSTAR study set in five TIA clinics (with
a median delay of 15 days from symptom onset to spe-
cialist review), the observed 90-day risk of stroke was
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seen within the first day [18]. This supports the concept
that patients are at highest risk in the period before they
encounter a specialist, and therefore the most effective
way of preventing a recurrent stroke is for the first doc-
tor who sees the patient to give medication prior to spe-
cialist review.
Despite recent advances in access to TIA clinics, the
national stroke audit, 2010, reports in its key messages
that it is still difficult to achieve appropriate timely ac-
cess for high risk patients in secondary care:
High-risk patients are still not being seen quickly
enough. A third of centres admit high-risk TIA in order
to access specialist assessment, although we know that
TIA patients generally sit outside of the acute stroke
unit when admitted. Only 10% of centres provide a
seven day a week outpatient based neurovascular
clinic for high-risk TIA. Access to carotid imaging for
high-risk TIA patients on the same day including the
weekend is only possible in 10% of centres. As imaging
is an integral part of specialist assessment its low level
of provision undermines the benefit of admitting high-
risk TIA patients. Almost half of centres admit low-risk
TIAs, which is probably a wasteful use of resources [19].
The proposed trial will investigate the role primary care
physicians (PCPs) might play in ensuring rapid treat-
ment – should they give immediate therapy, or simply
ensure prompt referral? The pilot work for the trial will also
help develop material of immediate NHS relevance – guid-
ance to primary care physicians on how to diagnose TIA
and data on the accuracy of primary care physician
diagnosis.
Current NICE guidelines recommend that patients with
suspected TIA or minor stroke should not routinely be ad-
mitted to hospital and should be assessed by a specialist
within 7 days (or 24 hours for people at particularly high
risk of stroke on the basis of their ABCD2 score) [6]. This
trial will compare rapid primary care initiation of second-
ary prevention with the current UK standard care as
described in the NICE guideline.
Aims
The aims of the trial are to determine the feasibility of a
randomised controlled trial, to analyse cost effectiveness
analysis and to ask: Should primary care physicians initiate
secondary preventative measures in addition to aspirin in
people they see with suspected TIA or minor stroke at the
time of referral to a specialist?
Questions to address:
1. Is randomisation at the individual patient level
possible?a. Is individual randomisation practical in the
primary care environment?
b. Is there evidence of contamination? That is, what
proportion and to what extent do patients
randomised to usual care receive the active
additional treatment?
2. What sample size (and what number of practices) is
required for a future trial?
a. What is the recruitment rate of patients to the
trial?
b. What is the follow-up rate throughout the trial?
c. What is the preliminary estimate of the primary
event rate (number of strokes at 90 days)?
3. Are proposed outcome measures for a future trial
feasible?
4. Werethere any adverse events?
5. How accurate is primary care physician diagnosis of
TIA?
Methods/Design
Outline of design
A pilot trial will recruit patients with symptoms suggest-
ive of TIA or minor stroke in general practices from the
catchment of three hospital TIA clinics (Birmingham,
Cambridge and Oxford) and the emergency department
in Cambridge (Figure 1). Embedded within this pilot trial
will be a diagnostic accuracy study comparing the initial
diagnosis made by the primary care physician with the
final diagnosis following review and investigation at the
specialist clinic. When a primary care physician sees a
patient with a history suggestive of TIA, are cord will be
made of whether TIA or a minor stroke is probable or
possible. All patients will then be referred to the TIA
clinic. Probable cases will be invited by the primary care
physician to enter the trial and the diagnostic accuracy
study; possible cases will be invited to enter the diagnos-
tic accuracy study only. Patients will be allocated by tele-
phone to additional pre-TIA clinic drug treatment and
usual care or usual care only, with allocation by a mini-
misation scheme using the following categories: TIA
clinic catchment area, primary care clinic type and
ABCD2 score. The TIA clinic will record the final diag-
nosis and adjust treatment accordingly. ‘Usual care’ im-
plies initiation of aspirin therapy and referral to the
specialist TIA clinic. The primary outcome will be the
number of strokes at 90 days. Semi-structured interviews
will be undertaken with the aim of determining how trial
procedures might be modified for the main trial.
Study population
The study population will comprise patients attending
general practice, out-of-hours general practice and emer-
gency departments with recent symptoms suggestive of
TIA or minor stroke. The primary care physician will
Assess for eligibility for RAPID TIA trial
Assign to RCT arm Assign to Diagnostic sub-study 
Exclude
Not meeting inclusion criteria
Declined to participate
Other reasons
Randomise
Allocate to Intervention 
plus usual care group
Allocate to usual care 
group
Attend TIA clinic Attend TIA clinic Attend TIA clinic
Day 90 Follow up Day 90 Follow up
Analysis Analysis Analysis
Day 90 Follow up
Figure 1 Cohort diagram of the RAPID-TIA trial.
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probable or possible. The former group will be eligible
for the trial. The latter group will not be eligible for the
trial, but will be eligible for the diagnostic accuracy
study.Identification of patients
Eligible patients will be drawn from general practices
in the catchment areas of the TIA clinics in Queen
Elizabeth Hospital (Birmingham), Walsall Manor Hospital
(Birmingham), Addenbrooke’s Hospital (Cambridge) and
John Radcliffe Hospital (Oxford), as well as the emergency
department in Cambridge. Oxfordshire practices that are
participating in the OXVASC study will be excluded from
the trial. For the pilot trial, we aim to recruit approxi-
mately ten practices from each area and one out-of-hours
general practice base from each area.Inclusion and exclusion criteria
Inclusion criteria
Patients presenting to a primary care physician with
symptoms suggestive of TIA or minor stroke (first and
recurrent, but only one event per patient in the trial).Exclusion criteria
Patients will be excluded if:
 The PCP considers that immediate emergency
admission is required for any reason. This will
include patients where symptoms have not
substantially resolved by the time they see the PCP.
PCPs will record reasons for exclusion.
 The patient has experienced a TIA or stroke within
the previous month.
 The PCP is not in equipoise.Recruitment
About 3 of the 1,000 people per annum who present
with symptoms suggestive of TIA or stroke are not man-
aged as inpatients [7]. Therefore, a practice with a list
size of 7,500 will have 20 patients per year that might be
referred into the study. If we assume that 5 people per
practice per year are actually randomised, this would
mean that 30 practices recruiting patients over a 1year
period would recruit 150 patients. Additional patients
will be recruited via out-of-hours general practice ser-
vices and emergency departments to reach a recruitment
target of 170, of whom we estimate 100 will be recruited
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tic accuracy study only.
Patient information and consent
Patients who are suspected of having a probable TIA or
minor stroke will receive information sheet A and be
invited to enter the pilot trial and diagnostic study.
Patients who are suspected as having a possible TIA or
minor stroke will receive information sheet B and be
invited to enter the diagnostic study only. Patients will
be given time to consider the information and to ask
questions. If the patient declines to enter the pilot or
diagnostic study, usual care will proceed. If the patient
accepts the invitation, usual care will proceed alongside
an assessment of eligibility for the trial. The primary
care physician will obtain written consent from eligible
patients who are willing to take part in either study.Randomisation
Telephone and internet randomisation will be available
utilising the resources of the Robertson Centre for
Biostatistics, part of the Glasgow Clinical Trials Unit. Dur-
ing the pilot phase, a minimisation scheme will be utilised
across the whole trial, using the following minimisation
factors: TIA clinic catchment area (Birmingham, Cambridge
or Oxford), clinic type (general practice, out-of-hours gen-
eral practice or emergency department) and risk of stroke
using the ABCD2 score (4 or more; less than 4). When an
eligible patient has given written consent to take part, the
primary care physician will ring the dedicated randomisation
number of the Clinical Trials Unit. Patient and site informa-
tion will be given to the trials unit who will assign the pa-
tient to additional treatment plus usual care or usual care
only.Sample size
This pilot study will be used to estimate the sample size
required for a future RCT. The diagnostic accuracy
study embedded within this pilot study requires a sam-
ple size of approximately 100 probable cases and 67
possible cases. GP diagnosis will be compared to TIA
clinic diagnosis in the light of relevant investigations.
We will not only be able to report on the predictive
value of GP diagnosis, but also sensitivity and specificity
since the ‘possible’ TIAs will also be referred to the
clinic (although they will not take part in the clinical
trial). If we have 100 probable and 67 possible cases re-
ferred, and assume sensitivity around 80%, predictive value
of around 67% and specificity around 60% from our previ-
ous work on modelling the impact of different patterns of
TIA services [20], then the confidence intervals will be be-
tween +/−10% for each of these parameters.Trial interventions
Intervention plus usual care group
Intervention group patients will be treated with additional
secondary prevention medications, unless there are clin-
ical contraindications, prior to referral to a specialist clinic.
Treatment will comprise of dual anti-platelets, blood-
pressure lowering medication, and simvastatin 40 mg. All
patients will then be referred to a specialist clinic as per
NICE guidelines (with the degree of urgency dictated by
the ABCD2 score) [6].
Dual anti-platelets
In patients not already on anti-platelet or anti-coagulant
therapy, aspirin 300 mg once daily will be started for the
first 2 weeks or until reduced by a specialist. Dipyrid-
amole MR 200 mg twice daily will be started in patients
not already on anti-platelet or anti-coagulation therapy
other than aspirin. Any anti-coagulation or anti-platelet
agents the patient is already taking will be continued.
Blood-pressure lowering medication
Unless BP is below 130 mmHg systolic on either of two
readings taken one minute apart or the patient is already
taking all three of a thiazide diuretic, ACE-inhibitor and
calcium channel blocker, then one of these three classes
of medication will be initiated according to the PCP’s
clinical choice. If the patient is already taking all three
drug classes, one agent should have its dose increased
within its licensed dosage according to the PCP’s clinical
choice.
Simvastatin 40 mg once daily
Simvastatin 40 mg daily will be started unless the patient
is already on statin treatment of equivalent intensity.
Clinicians should check liver function or renal func-
tion when starting statins or blood-pressure lowering
medication according to their usual practice, but results
are not mandatory prior to initiating treatment.
Usual care group
This is the control group. If patients are not already on
anti-platelet therapy, a loading dose of aspirin will be ad-
ministered (300 mg daily) and patients will be referred
to a specialist clinic as per NICE guidelines (with the de-
gree of urgency dictated by the ABCD2 score) [6]. All
patients will be instructed to continue with their usual
medication unless a clinician makes a specific decision
to alter it for any reason.
Diagnostic accuracy study
All patients who consent will be entered into the diag-
nostic study; patients with a diagnosis of possible TIA or
minor stroke will be entered only into the diagnostic
study.
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TIA clinic referral form. In addition, the PCP will record the
presence or absence of symptoms, signs and past medical
history relevant to the diagnosis of TIA, including individual
features to enable the ABCD2 score to be calculated: age,
blood pressure, clinical features including presence of unilat-
eral weakness and speech impairment, duration of symp-
toms and diabetes [5]. The PCP will provide a level of
certainty of diagnosis based upon clinical judgement: prob-
able or possible.
All patients will then be referred to a specialist
clinic as per NICE guidelines (with the degree of ur-
gency dictated by the ABCD2 score) [6]. At the TIA
clinic, the diagnosis, ABCD2 score and clinical fea-
tures will be recorded. Patients will be asked to give
consent that their clinical notes can be reviewed to
ascertain their final diagnosis (as a final diagnosis
may not be reached at the initial specialist appointment).
Summary of procedures and staffroles
Throughout the trial, the primary care physicians will
be instructed to follow usual practice, which should
be consistent with the 2008 NICE stroke guidelines
[6]. All patients with suspected TIA or minor stroke
should be continued on their anti-platelet treatment
or started on aspirin 300 mg daily unless there are
contraindications and referred to a specialist clinic
(with the degree of urgency dictated by the ABCD2
score) [6]. The intervention group will receive treat-
ment additional to this usual care.
Initial presentation in daytime general practice
Participating general practices have a lead GP, who
coordinates recruitment into the trial. Patients may
present with suspected TIA at any time to a GP in
the practice, who may be assisted in aspects of pa-
tient care by a practice nurse. When a patient pre-
sents, the clinician will take a history, examine the
patient and come to an initial diagnosis of possible or
probable TIA or minor stroke as per usual practice,
and then:
1. Inform the patient of the suspected diagnosis as per
usual practice.
2. Discuss the information sheet with the patient.
3. Confirm the inclusion and exclusion criteria.
The patient will be given time to consider the informa-
tion and to ask questions. The clinician will then:
4. Obtain informed consent if the patient is willing to
take part.
5. Record clinical features and whether TIA is probable
or possible.For patients diagnosed with probable TIA or minor
stroke, the clinician will also undertake the following:
6. Consider the relative indications and
contraindications to therapy.
7. Take the patient’s blood pressure.
8. Record any current medication.
9. Randomise the patient to the intervention or control
arm.
10. Prescribe and dispense the allocated medication.
11. Ask the patient to bring their medication to the
specialist clinic.
Finally, all patients will be referred to the TIA clinic
with urgency determined by local guidelines. The GP
will also arrange any additional appropriate follow-up
consistent with usual practice.
Initial presentation in out-of-hours general practice
Out of the hours of 8am to 6.30pm Monday to Friday,
GP care is usually provided by GPs who are not from
the patient’s weekday general practice. A limited number
of out-of-hours general practitioners will be trained to
recruit patients into the trial. When a patient presents to
a trained out-of-hours GP, the GP will take a history,
examine the patient and come to an initial diagnosis of
possible or probable TIA or minor stroke as per usual
practice, and then:
1. Inform the patient of the suspected diagnosis as per
usual practice.
2. Discuss the information sheet with the patient.
3. Confirm the inclusion and exclusion criteria.
The patient will be given time to consider the informa-
tion and to ask questions. The GP will then:
4. Obtain informed consent if the patient is willing to
take part.
5. Record clinical features and whether TIA is probable
or possible.
For patients diagnosed with probable TIA or minor
stroke, the GP will also undertake the following:
6. Consider the relative indications and
contraindications to therapy.
7. Take the patient’s blood pressure.
8. Record any current medication.
9. Randomise the patient to the intervention or control
arm.
10. Prescribe and dispense the allocated medication.
11. Ask the patient to bring their medication to the
specialist clinic.
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with urgency determined by local guidelines and the
daytime general practice informed by the time it re-
opens. The GP will also arrange any additional appropri-
ate follow-up consistent with usual practice.
Initial presentation in the emergency department
Participating emergency departments will have a team of
specialist nurses who support recruitment into the trial
and recruitment will only occur when a specialist nurse
is available. When a patient presents, the emergency de-
partment doctor will take a history, examine the patient
and come to an initial diagnosis of possible or probable
TIA or minor stroke as per usual practice and then:
1. Inform the patient of the suspected diagnosis as per
usual practice and contact the specialist nurse.
The specialist nurse will then:
2. Discuss the information sheet with the patient.
3. Confirm the inclusion and exclusion criteria.
The patient will be given time to consider the informa-
tion and to ask questions. The specialist nurse, sup-
ported by the emergency department doctor, will then:
4. Obtain informed consent if the patient is willing to
take part.
5. Record clinical features and whether TIA is probable
or possible.
For patients diagnosed with probable TIA or minor
stroke, the specialist nurse, supported by the emergency
department doctor, will also undertake the following:
6. Consider the relative indications and
contraindications to therapy.
7. Take the patient’s blood pressure.
8. Record any current medication.
9. Randomise the patient to the intervention or control
arm.
10. Prescribe and dispense the allocated medication.
11. Ask the patient to bring their medication to the
specialist clinic.
Finally, all patients will be referred to the TIA clinic
with urgency determined by local guidelines. The emer-
gency department doctor will also arrange any additional
appropriate follow-up consistent with usual practice.
Specialist clinic
All patients will have been referred to the TIA clinic as
per local protocol consistent with NICE guidelines andtherefore will usually be reviewed within 7 days of symp-
tom onset (or within 24 hours for higher risk TIAs).
Specialists will manage patients according to their usual
practice, including changing any medication started by
the primary care physician. In addition, the specialist
doctor, supported by nursing staff, willrecord clinical
features, ABCD2 score, blood pressure, final diagnosis,
current medication, persistence with primary care initi-
ated medication and changes to medication.
Additionally, the research nurse will check the pa-
tient’s hospital record for a final diagnosis when this
is available if it is not confirmed during the initial
TIA clinic attendance; the research nurse will also ob-
tain an up-to-date medication list from the patient’s
GP record if this has not been provided at initial
presentation.
Outcome measures
Initial assessments of outcome measures for a future
RCT will be made to assess their feasibility. Addi-
tional pilot RCT outcome measures will also be
recorded specifically to examine recruitment feasibi-
lity. The diagnostic accuracy study will compare the
primary care physician’s and the specialist’sdiagnoses
and risk stratification scores. The same outcomes will
be measured for both the pilot RCT and diagnostic
studies.
Outcome measures for the future randomised control trial
Primary outcome measure The number ofstrokes within
90 days of randomisation.
Secondary outcome measures
Clinical outcomes within 90 days of randomisation:
 All vascular events
 All major bleeding
 Death
 Ischaemic stroke
 Haemorrhagic stroke
 Fatal stroke
 Disabling stroke
 Non-disabling stroke
 TIA
We will also explore the benefit of analysing clinical
outcomes at different lengths of time, including 7 days
from randomisation, 7 and 90 days from first symptoms,
and between randomisation and the first specialist
appointment.
The definition of a TIA is ‘a transient episode of
neurological dysfunction caused by focal brain, spinal
cord, or retinal ischemia, without acute infarction’,
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ate imaging when available [21].
Adverse events
Unplanned hospitalisation and falls between entry into
the trial and the first specialist appointment will be
reported as possible adverse events.GP contacts will be
recorded. If Read codes suggest treatment has led to
additional GP contacts, the research team will retro-
spectively analyse the GP record for further details.
Quality of life
Quality of life will be measured using the EQ-5D ques-
tionnaire at 90 days.
Cost data
A cost-effectiveness analysis will form a component of
the future RCT. During the pilot phase, 90-day cost data
will be gathered to develop this analysis, including:
 Drug usage
 Investigations
 Hospital admissions
 Outpatient admissions
 GP contacts
Process of care measures
The process of care measures are the patient’s blood
pressure at 90 days and serum cholesterol at 90 days.
Persistence with treatment at first specialist appointment
and persistence with treatment at 90 days will be
recorded.
Additional outcome measures for the pilot randomised
control trial
Recruitment rate
 Number assessed for eligibility by site (emergency
department, out-of-hours general practice or general
practice).
 Number recruited into the pilot RCT by site.
 Number who received the allocated intervention by
site (including the nature of receipt of intervention
group medications in the control group).
 Number followed up at 90 days by site.
 Basic demographic data and data on the
presentation of the patient to the site will be
collected on patients excluded or missed from the
study by each site to help determine the feasibility of
the trial.
 TIA clinics in participating hospitals will be audited
to cross-check the data collected from each site and
diagnoses of patients from participating practices
will be obtained.Sample size calculation
The proportion of patients experiencing a stroke within
90 days by allocation will be used to assist the sample
size calculation for the future RCT. Side effects, toler-
ability and quality of life will be assessed from the rea-
sons given by patients for omitting or stopping
medication and their responses to the standard side-
effect questionnaire at 90 days.
Outcome measures for the diagnostic accuracy study
 Clinic’s diagnosis of TIA or minor stroke compared
with the primary care physician’s diagnosis of
possible or probable TIA and with the primary care
physician’s ABCD2 score.
 Clinic-defined ABCD2 score compared with primary
care physician’s ABCD2 score.
 Features recognised by primary care physicians that
predict TIA.
 Clinical features recognised by primary care
physicians but not by specialists and vice versa.
 How well the clinical features and ABCD2 score
predict for anterior versus posterior circulation
events.
Follow-up
There will be a 90-day follow-up clinic at the hospital.
This will be supplemented by a review of GP and hos-
pital records, flagging with the NHS Central Register
and telephone contact or home visits for patients who
do not or cannot attend the 90-day follow-up clinic.
These follow-up mechanisms will:
 Confirm the final diagnosis.
 Record the patient’s blood pressure and serum
cholesterol at 90 days.
 Identify primary and secondary outcomes.
 Monitor for serious adverse events and deaths.
 Record any changes in treatment and persistence
with medication at 90 days.
 Collate cost data.
 Assess the patient’s quality of life at 90 days.
 Record side effects.
Prior to contacting participants for a follow-up, their
health status will be established via their GPs to establish
that they are not deceased and to ascertain whether their
mental capacity has been lost. Participants identified as
having lost capacity will be contacted and an appropriate
consultee appointed. Detailed information about the trial
will be provided to the consultee, and if in agreement an
appointment will be made for the participant’s follow-up
visit, at which the consultee must be present and must
sign a declaration form to confirm their accordance.
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the 90-day follow-up clinic will be sent to the patients’ GP.
Where strokes are identified, anonymised copies of the
relevant clinical information (from GP and hospital re-
cords, post-mortem reports, scan reports and so on) will
be obtained and sent to an independent end-point com-
mittee, who will be blinded to treatment allocation. In-
dependently of each other, the end-point committee will
determine whether or not a stroke occurred, and if so,
what sort of a stroke it was. Characterisation will in-
clude: ischaemic or haemorrhagic and disabling, non-
disabling or TIA. Secondary outcomes will also include
all vascular events, all major bleeding and deaths. Rele-
vant clinical records will be scrutinised by an independ-
ent expert blinded to treatment allocation, who will
determine whether or not a vascular event or major
bleeding occurred, and what it was using standard case
definitions. All hospital admissions will be scrutinised
for possible adverse events and the clinical records sent
to an independent expert for review.
We will follow up all patients, including those in the
RCT and the diagnostic study.
Analysis
For the statistical analysis,baseline, TIA clinic and follow-up
variables will be summarised by treatment group and over-
all. Categorical variables will be summarised by the number
and percentage of subjects in each category. Continuous
variables will be summarised using the mean, median, stand-
ard deviation, interquartile range and minimum and max-
imum values. For the main trial, logistic regression analysis
of the primary and secondary outcomes will determine the
efficacy of rapid drug treatment initiation after adjusting for
the variables for catchment area, clinic type and ABCD2
score. Analysis will be according to the intention-to-treat
principle and the treatment effect will be expressed as an
odds ratio and its corresponding 95% confidence interval.
The influence of missing data on the robustness of the find-
ings will be explored in sensitivity analyses (replacement by
last value, mean of series and multiple imputation). All stat-
istical analyses will be pre-specified in a comprehensive stat-
istical analysis plan, which will be agreed by the trial steering
committee in advance of the final database lock.
Clinical outcomes will also be analysed according to
the following sub-groups:
 Specialist diagnosis of non-TIA, TIA or stroke.
 Primary care physician’s diagnosis of possible or
probable TIA.
 Specialist’s ABCD2 score.
 Primary care physician’s ABCD2 score (both as
recorded by the minimisation hotline and the case
report forms).
 Baseline therapy. Recruitment site by location (Birmingham,
Cambridge or Oxford) and clinic type (out-of-hours
general practice, daytime general practice or
emergency department).
 First TIA or stroke versus recurrent TIA or stroke.
We will analyse the TIA versus minor stroke outcome
rates in both RCT groups to exclude diagnostic bias.
Ethical approval
The RAPID-TIA protocol was granted ethical approval
by the Cambridgeshire 3 Research Ethics Committee
(REC reference 11 EE 0040) and is compliant with the
Helsinki Declaration.
Discussion
The main aims of the RAPID-TIA pilot trial are to de-
termine the feasibility of a randomised controlled trial,
to analyse cost effectiveness and to ask: Should general
practitioners and emergency doctors initiate secondary
preventative measures in addition to aspirin in people
they see with suspected TIA or minor stroke at the time
of referral to a specialist?
While there are potential benefits of primary care initi-
ation of treatment, potential adverse effects need to be
considered. These include the risk of extension of haem-
orrhagic stroke from dual anti-platelet treatment, uncer-
tainty about the effect of early statin treatment and
unnecessary treatment due to overdiagnosis.
Anti-platelet agents decrease the risk of stroke and
other cardiovascular disease but increase the risk of
bleeding; both of these effects are increased by dual anti-
platelet agents [22,23]. Although there is controversy
over whether people experiencing a haemorrhagic stroke
may have their stroke worsened by anti-platelet agents
[24-27], it is reasonable to be alert to the possibility that
dual anti-platelets may have a poorer prognosis if they
are inadvertently given to a patient experiencing a haem-
orrhagic stroke. However, because ischaemic stroke is
substantially more common than haemorrhagic stroke, it
is currently standard practice to treat patients with TIA
or minor stroke with a single anti-platelet agent (aspirin)
before specialist review or brain imaging, on the basis
that any delay in treatment will increase the risk of re-
current stroke [6]. Patients whose neurological symp-
toms have not substantially resolved are at higher risk of
having had a haemorrhagic event, and therefore will be
excluded from this trial. Haemorrhagic strokes occurring
during the pilot or main trial will be recorded as signifi-
cant adverse events.
There is currently no evidence that rapid administra-
tion of statin treatment is beneficial. The FASTER study
investigated treatment with simvastatin 40 mg once daily
versus a placebo in 392 patients within 24 hours of a
Edwards et al. Trials 2013, 14:194 Page 10 of 11
http://www.trialsjournal.com/content/14/1/194stroke or TIA and failed to demonstrate whether this
was either harmful or beneficial (the absolute risk in-
crease of stroke within 90 days was 3.3%; the 95% confi-
dence interval was −2.3% to 8.9%; P=0.25) [12].
However, there is evidence that statin treatment reduces
the incidence of recurrent stroke in the long term in
people who have experienced a stroke or TIA [28-30]
and statin treatment is recommended for all patients
who experience ischaemic stroke/TIA [6].
Approximately 50% of people referred to TIA clinics have
not experienced a TIA or minor stroke [31]. Common alter-
nate diagnoses include migraine, faints, vertigo and epilepsy
[32]. It is therefore likely that this trial will increase the num-
ber of people who are given blood pressure treatment, statin
therapy and anti-platelet agents for the brief period (usually
less than 7 days) before they are reviewed by the specialist
clinic. However, all these agents are commonly used in pri-
mary care to prevent cardiovascular disease, and it is un-
likely that 1 to 7 days of unnecessary treatment will cause
substantial harm – indeed, since clinicians use cardiovascu-
lar risk factors to assess the likelihood of TIA or minor
stroke, many patients with alternative diagnoses may benefit
from these drugs and the focus on their cardiovascular risk
that a suspected diagnosis brings. Significant adverse events
that occur prior to specialist clinic attendance will, however,
be recorded.
Given that PCPs currently refer a high proportion of
patients without TIA to TIA clinics (threatening to in-
crease the sample size requirement), this pilot study will
estimate the proportion of patients with TIA who are
likely to be referred in the main trial, and gather evi-
dence to support improved diagnostic accuracy in pri-
mary care. Currently diagnostic or referral support tools
have not been trialled in primary care and as such there
is no current evidence base to inform an intervention to
improve the diagnostic accuracy of TIA referrals from
PCPs. Within the pilot study, referring PCPs will have a
choice as to whether to diagnose patients as probable
TIA or minor stroke (and enter them into the treatment
trial) or as possible TIA or minor stroke (and not enter
them into the treatment trial). It is likely that this choice
will mean that more than 50% of patients entered into
the treatment trial will have experienced a TIA or minor
stroke, and this pilot study will gather data on whether
diagnostic accuracy is higher in the “probable TIA”
group.
This pilot study will therefore both test the feasibility
of the main study and provide novel data on diagnostic
accuracy in primary care and the primary care recorded
clinical features that are associated with a positive spe-
cialist diagnosis. The main study will inform national
stroke prevention policy in patients with suspected TIA
and contribute significantly to the evidence base for
managing TIA in primary care.The study so far has experienced some difficulties. Re-
cruitment occurred in real time and this can prove diffi-
cult depending on the demands the PCP is experiencing at
the time of recruitment, such as a late-running clinic. This
led to patients meeting the inclusion criteria being missed.
We are also experiencing low recruitment rates. To try to
understand why this is occurring we are carrying out au-
dits on the participating GP practices, as well as the par-
ticipating TIA clinics, to enable us to quantify the reasons
why patients were not recruited into the study.
Trial status
The study started recruiting participants in November
2011, and recruitment closed 31 December 2012.
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